Dubois Valérie, Amokrane Kahina, Crocchiolo Roberto, Fort Marylise, Guillaume Nicolas, Kennel Anne, Michiels Sandra, Ralazamahaleo Mamy, Rouzaire Paul-Olivier, Yakoub-Agha Ibrahim, Faucher Catherine
Établissement Français du Sang, laboratoire Histocompatibilité, 69150 Décines, France.
Hôpital Saint Louis, laboratoire d'Immunologie Histocompatibilité, 75010 Paris, France.
Bull Cancer. 2021 Dec;108(12S):S45-S52. doi: 10.1016/j.bulcan.2021.01.024. Epub 2021 May 7.
Standardization of histocompatibility tests for allogeneic hematopoietic cell transplants, harmonization of information transmitted to clinicians are part of quality improvement and optimization of human and economic resources. New HLA typing technologies provide high-resolution information within a reasonable time frame. Knowledge of high-resolution HLA typing for the patient and their relatives is essential for a better interpretation of compatibilities. HLA-DPB1 typing must be considered in transplant field regardless of the donor type. The benefits of using search and match programs are considerable. It saves time and reduces additional typing costs by providing rapid information about the likelihood to identify a matched unrelated donor. A backup therapy considering alternative cell sources or treatment can therefore be quickly implemented. The importance of knowledge and consideration of patient immunization for donor choice was explored in previous workshops of the SFGM-TC (2018 and 2019). The published recommendations remain applicable. The routine follow-up protocol and in case of desensitization will be detailed here. This harmonization must be accompanied by the standardization of information to be returned to the clinician regarding the donor finding possibilities for the patient. This will guarantee a similar quality level in every center.
异基因造血细胞移植组织相容性检测的标准化、向临床医生传递信息的协调一致,是质量改进以及人力和经济资源优化的一部分。新的人类白细胞抗原(HLA)分型技术能在合理时间内提供高分辨率信息。了解患者及其亲属的高分辨率HLA分型对于更好地解读相容性至关重要。在移植领域,无论供体类型如何,都必须考虑HLA-DPB1分型。使用搜索和匹配程序的益处相当可观。它节省时间,并通过快速提供有关识别匹配无关供体可能性的信息来降低额外的分型成本。因此,可以迅速实施考虑替代细胞来源或治疗方法的备用治疗方案。在SFGM-TC(2018年和2019年)之前的研讨会上探讨了了解并考虑患者免疫情况对供体选择的重要性。已发布的建议仍然适用。这里将详细介绍常规随访方案以及脱敏情况下的方案。这种协调一致必须伴随着向临床医生反馈的有关患者供体寻找可能性信息的标准化。这将确保每个中心都有相似的质量水平。